{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:01:39Z","timestamp":1793847699299,"version":"4.6.1"},"reference-count":209,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1053,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1186\/s13613-023-01134-9","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T05:02:19Z","timestamp":1683349339000},"page":"39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Antibiotic stewardship in the ICU: time to shift into overdrive"],"prefix":"10.1016","volume":"13","author":[{"given":"David","family":"Mokrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Chommeloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pineton de Chambrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"H\u00e9kimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-2705","authenticated-orcid":false,"given":"Charles-Edouard","family":"Luyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-023-01134-9_bb0010","unstructured":"Sant\u00e9 Publique France. Surveillance de la consommation des antibiotiques et des r\u00e9sistances bact\u00e9riennes en \u00e9tablissement de sant\u00e9. Mission SPARES, r\u00e9sultats 2019. 2021;81."},{"key":"10.1186\/s13613-023-01134-9_bb0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"10.1186\/s13613-023-01134-9_bb0020","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"10.1186\/s13613-023-01134-9_bb0025","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jamainternmed.2014.8273","article-title":"Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection","volume":"175","author":"Brown","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb0030","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/CCM.0000000000000746","article-title":"Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime","volume":"43","author":"Jensen","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet"},{"key":"10.1186\/s13613-023-01134-9_bb0040","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb0045","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archinte.162.13.1515","article-title":"Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned","volume":"162","author":"Landman","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)17907-0","article-title":"Outpatient antibiotic use in Europe and association with resistance: a cross-national database study","volume":"365","author":"ESAC Project Group","year":"2005","journal-title":"Lancet"},{"key":"10.1186\/s13613-023-01134-9_bb0055","unstructured":"European Centre for Disease Prevention and Control, World Health Organization. Antimicrobial resistance surveillance in Europe: 2022 : 2020 data. LU: Publications Office; 2022. Disponible sur: https:\/\/data.europa.eu\/doi\/https:\/\/doi.org\/10.2900\/112339. Accessed 17 Nov 2022."},{"key":"10.1186\/s13613-023-01134-9_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1186\/s13613-023-01134-9_bb0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM199708143370701","article-title":"The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance","volume":"337","author":"Sepp\u00e4l\u00e4","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1186\/s13613-023-01134-9_bb0075","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archinte.163.8.972","article-title":"Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity","volume":"163","author":"Hecker","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cmi.2017.08.026","article-title":"What is antimicrobial stewardship?","volume":"23","author":"ESGAP (ESCMID Study Group for Antimicrobial stewardshiP)","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0085","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0090","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency care for sepsis","volume":"376","author":"Seymour","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1186\/s13613-023-01134-9_bb0095","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1164\/rccm.201609-1848OC","article-title":"The timing of early antibiotics and hospital mortality in sepsis","volume":"196","author":"Liu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0100","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000005357","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0105","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1473-3099(12)70151-2","article-title":"Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study","volume":"12","author":"Hranjec","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13054-021-03660-z","article-title":"Impact of a restrictive antibiotic policy on the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an endemic region: a before-and-after, propensity-matched cohort study in a Caribbean intensive care unit","volume":"25","author":"Le Terrier","year":"2021","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2213-2600(17)30469-1","article-title":"Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial","volume":"6","author":"Alam","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1186\/s13613-023-01134-9_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-016-1266-9","article-title":"Diagnosing sepsis is subjective and highly variable: a survey of intensivists using case vignettes","volume":"20","author":"Rhee","year":"2016","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0125","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650580","article-title":"Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department","volume":"50","author":"Heffner","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-015-1035-1","article-title":"Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study","volume":"19","author":"Klein Klouwenberg","year":"2015","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0135","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13054-016-1537-5","article-title":"Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study","volume":"20","author":"Contou","year":"2016","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0140","doi-asserted-by":"crossref","unstructured":"De Waele JJ, Girardis M, Martin-Loeches I. Source control in the management of sepsis and septic shock. Intensive Care Med. 2022;","DOI":"10.1007\/s00134-022-06852-5"},{"key":"10.1186\/s13613-023-01134-9_bb0145","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00003246-199802000-00017","article-title":"Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial treatments","volume":"26","author":"Souweine","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-132-8-200004180-00004","article-title":"Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial","volume":"132","author":"Fagon","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb0155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.202106-1354OC","article-title":"Bacterial superinfection pneumonia in patients mechanically ventilated for COVID-19 pneumonia","volume":"204","author":"Pickens","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0160","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/CCM.0b013e318287f713","article-title":"Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures","volume":"41","author":"Raman","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0165","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1097\/CCM.0b013e318251517a","article-title":"Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients","volume":"40","author":"Layios","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0170","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"10.1186\/s13613-023-01134-9_bb0175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1802670","article-title":"Procalcitonin-guided use of antibiotics for lower respiratory tract infection","volume":"379","author":"Huang","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1186\/s13613-023-01134-9_bb0180","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ijantimicag.2015.10.012","article-title":"Procalcitonin to guide antibiotic therapy in the ICU","volume":"46","author":"Br\u00e9chot","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01134-9_bb0185","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.3390\/jcm11154366","article-title":"Potential of multiplex polymerase chain reaction performed on protected telescope catheter samples for early adaptation of antimicrobial therapy in ARDS patients","volume":"11","author":"Razazi","year":"2022","journal-title":"J Clin Med"},{"key":"10.1186\/s13613-023-01134-9_bb0190","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-2600(22)00086-8","article-title":"Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial","volume":"10","author":"Darie","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1186\/s13613-023-01134-9_bb0195","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s13054-020-03102-2","article-title":"Usefulness of point-of-care multiplex PCR to rapidly identify pathogens responsible for ventilator-associated pneumonia and their resistance to antibiotics: an observational study","volume":"24","author":"Luyt","year":"2020","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0200","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13054-020-03067-2","article-title":"Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia","volume":"24","author":"Peiffer-Smadja","year":"2020","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0205","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00134-016-4239-1","article-title":"Does this patient have VAP?","volume":"42","author":"Chastre","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/ajrccm.157.2.9705064","article-title":"Ventilator-associated pneumonia caused by potentially drug-resistant bacteria","volume":"157","author":"Trouillet","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0215","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1186\/s13613-023-01134-9_bb0220","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/AAC.01823-12","article-title":"Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients","volume":"57","author":"Armand-Lef\u00e8vre","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1040841X.2013.875515","article-title":"Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients\u2014review of the literature from a clinical perspective","volume":"42","author":"Biehl","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"10.1186\/s13613-023-01134-9_bb0230","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00134-012-2675-0","article-title":"Clinical impact and risk factors for colonization with extended-spectrum \u03b2-lactamase-producing bacteria in the intensive care unit","volume":"38","author":"Razazi","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0235","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jac\/dkv423","article-title":"Colonization and infection with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?","volume":"71","author":"Barbier","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0240","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00134-018-5154-4","article-title":"Infection-related ventilator-associated complications in ICU patients colonised with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"44","author":"Barbier","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0245","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jinf.2020.02.023","article-title":"Quantifying risk of disease due to extended-spectrum \u03b2-lactamase producing Enterobacteriaceae in patients who are colonized at ICU admission","volume":"80","author":"Razazi","year":"2020","journal-title":"J Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0250","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1086\/669858","article-title":"Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum \u03b2-lactamase-producing enterobacteriaceae on hospital admission","volume":"34","author":"Johnson","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1186\/s13613-023-01134-9_bb0255","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.00009-11","article-title":"Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system","volume":"55","author":"Tumbarello","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13613-017-0237-x","article-title":"Relation between presence of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in systematic rectal swabs and respiratory tract specimens in ICU patients","volume":"7","author":"Carbonne","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-023-01134-9_bb0265","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.cmi.2017.07.030","article-title":"\u03b2 LACTA test performance for detection of extended-spectrum \u03b2-lactamase-producing Gram-negative bacilli directly on bronchial aspirates samples: a validation study","volume":"24","author":"Gallah","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024561","volume":"9","author":"Garnier","year":"2019","journal-title":"BMJ Open"},{"key":"10.1186\/s13613-023-01134-9_bb0275","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02067-21","article-title":"Selection of AmpC \u03b2-lactamase variants and metallo-\u03b2-lactamases leading to ceftolozane\/tazobactam and ceftazidime\/avibactam resistance during treatment of MDR\/XDR Pseudomonas aeruginosa infections","volume":"66","author":"Ruedas-L\u00f3pez","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0280","doi-asserted-by":"crossref","unstructured":"Sadek M, Le Guern R, Kipnis E, Gosset P, Poirel L, Dessein R, et al. Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2022;","DOI":"10.1007\/s10096-022-04526-0"},{"key":"10.1186\/s13613-023-01134-9_bb0285","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in US hospitalized patients, 2012\u20132017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1186\/s13613-023-01134-9_bb0290","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0295","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13613-018-0444-0","article-title":"Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU","volume":"8","author":"Leone","year":"2018","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-023-01134-9_bb0300","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0305","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1513\/AnnalsATS.201902-162OC","article-title":"potential impact of hospital-acquired pneumonia guidelines on empiric antibiotics. An evaluation of 113 veterans affairs medical centers","volume":"16","author":"Bostwick","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1186\/s13613-023-01134-9_bb0310","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamainternmed.2019.7495","article-title":"Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia","volume":"180","author":"Jones","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2018.10.014","article-title":"Outcomes associated with de-escalating therapy for methicillin-resistant Staphylococcus aureus in culture-negative nosocomial pneumonia","volume":"155","author":"Cowley","year":"2019","journal-title":"Chest"},{"key":"10.1186\/s13613-023-01134-9_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy024","article-title":"The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA Pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications","volume":"67","author":"Parente","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0325","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/antibiotics11020239","article-title":"Detection of methicillin-resistant Staphylococcus aureus infections using molecular methods","volume":"11","author":"Tenover","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01134-9_bb0330","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/cid\/cis783","article-title":"Nosocomial infections in adult cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation","volume":"55","author":"Schmidt","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0335","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/ciy631","article-title":"A Therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy","volume":"68","author":"Maruyama","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0340","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/AAC.01365-09","article-title":"Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis","volume":"54","author":"Micek","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0345","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1086\/527038","article-title":"The difference between adequate and appropriate antimicrobial treatment","volume":"46","author":"Siempos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0350","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.medmal.2013.01.006","article-title":"Alternatives to carbapenems in ESBL-producing Escherichia coli infections","volume":"43","author":"Fournier","year":"2013","journal-title":"Med Mal Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0355","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/cid\/cix186","article-title":"Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: a prospective observational cohort study","volume":"64","author":"Ong","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0360","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1001\/jama.2012.5833","article-title":"Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial","volume":"307","author":"Brunkhorst","year":"2012","journal-title":"JAMA"},{"key":"10.1186\/s13613-023-01134-9_bb0365","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/AAC.00115-10","article-title":"Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms","volume":"54","author":"Mart\u00ednez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6","key":"10.1186\/s13613-023-01134-9_bb0370","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2014full version","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003344.pub3","article-title":"Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1186\/s13613-023-01134-9_bb0380","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1186\/cc13095","article-title":"Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance","volume":"17","author":"Adrie","year":"2013","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0385","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","article-title":"Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy","volume":"35","author":"Garnacho-Montero","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0390","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.47.9.2756-2764.2003","article-title":"Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia","volume":"47","author":"Chamot","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0395","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cid\/cit223","article-title":"Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort","volume":"57","author":"Pe\u00f1a","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0400","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/CCM.0b013e3181eb3ccd","article-title":"Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis","volume":"38","author":"Kumar","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0405","doi-asserted-by":"crossref","first-page":"e00079","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1186\/s13613-023-01134-9_bb0410","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0415","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0420","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cmi.2016.01.016","article-title":"Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"22","author":"Falcone","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0425","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0430","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0435","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00134-019-05866-w","volume":"46","author":"Tabah","year":"2020","journal-title":"Intensive Care Med"},{"issue":"649","key":"10.1186\/s13613-023-01134-9_bb0440","first-page":"e1","article-title":"Elaboration of a consensual definition of de-escalation allowing a ranking of \u03b2-lactams","volume":"21","author":"Weiss","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0445","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/677633","article-title":"Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach","volume":"35","author":"Madaras-Kelly","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1186\/s13613-023-01134-9_bb0450","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijantimicag.2015.08.013","article-title":"Carbapenem use in French hospitals: a nationwide survey at the patient level","volume":"46","author":"Gauzit","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01134-9_bb0455","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00134-013-3077-7","article-title":"De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock","volume":"40","author":"Garnacho-Montero","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0460","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00134-013-3148-9","article-title":"De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study","volume":"40","author":"Mokart","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0465","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00134-014-3411-8","article-title":"De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial","volume":"40","author":"Leone","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0470","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00134-016-4301-z","article-title":"Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study","volume":"42","author":"De Bus","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0475","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00134-016-4448-7","article-title":"De-escalation of pivotal beta-lactam in ventilator-associated pneumonia does not impact outcome and marginally affects MDR acquisition","volume":"42","author":"Weiss","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0480","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00134-019-05871-z","article-title":"Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions\u2014a viewpoint of experts","volume":"46","author":"De Waele","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0485","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s12325-020-01390-2","article-title":"Antimicrobial de-escalation in the ICU: from recommendations to level of evidence","volume":"37","author":"Lakbar","year":"2020","journal-title":"Adv Ther"},{"key":"10.1186\/s13613-023-01134-9_bb0490","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13613-021-00976-5","article-title":"The role of the microbiota in the management of intensive care patients","volume":"12","author":"Szychowiak","year":"2022","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-023-01134-9_bb0495","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1186\/s13613-023-01134-9_bb0500","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nri3535","article-title":"Microbiota-mediated colonization resistance against intestinal pathogens","volume":"13","author":"Buffie","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1186\/s13613-023-01134-9_bb0505","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cmi.2017.09.017","article-title":"Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage","volume":"24","author":"Rupp\u00e9","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0510","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijantimicag.2018.08.026","article-title":"Carbapenems and alternative \u03b2-lactams for the treatment of infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance?","volume":"52","author":"Woerther","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01134-9_bb0515","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/jac\/dkz279","article-title":"Antibiotics with activity against intestinal anaerobes and the hazard of acquired colonization with ceftriaxone-resistant Gram-negative pathogens in ICU patients: a propensity score-based analysis","volume":"74","author":"Boutrot","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0520","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00134-018-5309-3","article-title":"The gut microbiota of critically ill patients: first steps in an unexplored world","volume":"44","author":"Rupp\u00e9","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0525","doi-asserted-by":"crossref","first-page":"1795492","DOI":"10.1080\/19490976.2020.1791677","article-title":"Long-term effects of antimicrobial drugs on the composition of the human gut microbiota","volume":"12","author":"Mulder","year":"2020","journal-title":"Gut Microbes"},{"key":"10.1186\/s13613-023-01134-9_bb0530","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/phar.2201","article-title":"Duration of exposure to antipseudomonal \u03b2-lactam antibiotics in the critically ill and development of new resistance","volume":"39","author":"Teshome","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1186\/s13613-023-01134-9_bb0535","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Extended-Spectrum Beta-Lactamases\u2013Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa\/Grupo de Estudio de Infecci\u00f3n Hospitalaria Group","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0540","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0545","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.02.001","article-title":"Use of non-carbapenem antibiotics to treat severe extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae infections in intensive care unit patients","volume":"53","author":"Luyt","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01134-9_bb0550","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0555","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dku351","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Shiber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0560","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1186\/s13613-023-01134-9_bb0565","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0570","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","article-title":"Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Proteus mirabilis","volume":"80","author":"Tsai","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0575","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.00135-13","article-title":"Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"57","author":"ESBL-REIPI\/GEIH Group","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0580","doi-asserted-by":"crossref","first-page":"e00276","DOI":"10.1128\/AAC.00276-17","article-title":"Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"61","author":"Cheng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0585","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0590","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmii.2015.08.012","article-title":"Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"50","author":"Lo","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0595","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix606","article-title":"Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae: results from the INCREMENT Cohort","volume":"65","author":"Palacios-Baena","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0600","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae : importance of inadequate initial antimicrobial treatment","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0605","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England","volume":"57","author":"Livermore","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106361","article-title":"Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study","volume":"58","author":"Delory","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01134-9_bb0615","unstructured":"Assistance Publique\u2014H\u00f4pitaux de Paris. Piperacillin-tazobactam and Temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase-producing Gram-negative Enterobacteriaceae in the intensive care unit. clinicaltrials.gov; 2022 oct. Report No.: NCT05565222https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05565222."},{"key":"10.1186\/s13613-023-01134-9_bb0620","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2022.21","article-title":"Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI)","volume":"2","author":"Vu","year":"2022","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1186\/s13613-023-01134-9_bb0625","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/antibiotics11101384","article-title":"Pragmatic comparison of piperacillin\/tazobactam versus carbapenems in treating patients with nosocomial pneumonia caused by extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"11","author":"Zha","year":"2022","journal-title":"Antibiotics"},{"key":"10.1186\/s13613-023-01134-9_bb0630","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0635","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/cid\/ciu055","article-title":"Editorial commentary: are blood concentrations enough for establishing pharmacokinetic\/pharmacodynamic relationships?","volume":"58","author":"Craig","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0640","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0650","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/AAC.38.5.931","article-title":"Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model","volume":"38","author":"Mouton","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0655","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01134-9_bb0660","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0665","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01134-9_bb0670","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0675","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","article-title":"Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis","volume":"46","author":"Rhodes","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0680","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0685","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/ciac506","article-title":"Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis","volume":"75","author":"Pai Mangalore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0690","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0695","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13613-017-0255-8","article-title":"Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects","volume":"7","author":"Neuville","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-023-01134-9_bb0700","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1186\/s13613-023-01134-9_bb0705","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","article-title":"Antibiotic resistance\u2014what\u2019s dosing got to do with it?","volume":"36","author":"Roberts","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0710","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/jac\/dkaa359","article-title":"Early therapeutic monitoring of \u03b2-lactams and associated therapy outcomes in critically ill patients","volume":"75","author":"Al-Shaer","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0715","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya","year":"2016","journal-title":"Neurology"},{"key":"10.1186\/s13613-023-01134-9_bb0720","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamasurg.2019.0569","article-title":"Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events","volume":"154","author":"Branch-Elliman","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1186\/s13613-023-01134-9_bb0725","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/cix947","article-title":"Risk of subsequent sepsis within 90 days after a hospital stay by type of antibiotic exposure","volume":"66","author":"Baggs","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0730","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.accpm.2017.11.006","article-title":"Hospital-acquired pneumonia in ICU","volume":"37","author":"Leone","year":"2018","journal-title":"Anaesthesia Critical Care & Pain Medicine"},{"key":"10.1186\/s13613-023-01134-9_bb0735","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"10.1186\/s13613-023-01134-9_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041290","article-title":"Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment","volume":"7","author":"Capellier","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1186\/s13613-023-01134-9_bb0745","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007577.pub3","article-title":"Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults","author":"Pugh","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1186\/s13613-023-01134-9_bb0750","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00134-022-06690-5","article-title":"Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial","volume":"48","author":"Bougl\u00e9","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0755","article-title":"Less is more? Antibiotic treatment duration in Pseudomonas aeruginosa ventilator-associated pneumonia","author":"Albin","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0760","article-title":"Less is more: a 7-day course of antibiotics is the evidence-based treatment for Pseudomonas aeruginosa ventilator-associated pneumonia","author":"Metersky","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0765","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13613-020-00775-4","article-title":"Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study","volume":"10","author":"Luyt","year":"2020","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-023-01134-9_bb0770","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00134-020-06323-9","article-title":"Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study","volume":"47","author":"Rouz\u00e9","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0775","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s15010-017-1020-5","article-title":"Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections","volume":"45","author":"Nelson","year":"2017","journal-title":"Infection"},{"key":"10.1186\/s13613-023-01134-9_bb0780","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/cid\/cix767","article-title":"Comparing the outcomes of adults with enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort","volume":"66","author":"Chotiprasitsakul","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0785","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10096-019-03467-5","article-title":"Short- versus long-course therapy in gram-negative bacilli bloodstream infections","volume":"38","author":"Sousa","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0790","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0795","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038300","article-title":"Bacteremia antibiotic length actually needed for clinical effectiveness (BALANCE) randomised clinical trial: study protocol","volume":"10","author":"Daneman","year":"2020","journal-title":"BMJ Open"},{"key":"10.1186\/s13613-023-01134-9_bb0800","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cmi.2018.09.018","article-title":"Impact of antimicrobial treatment duration on outcome of Staphylococcus aureus bacteraemia: a cohort study","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0805","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.cmi.2019.07.019","article-title":"Association between treatment duration and mortality or relapse in adult patients with Staphylococcus aureus bacteraemia: a retrospective cohort study","volume":"26","author":"Abbas","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0810","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13063-019-3357-9","article-title":"Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial","volume":"20","author":"Thorlacius-Ussing","year":"2019","journal-title":"Trials"},{"key":"10.1186\/s13613-023-01134-9_bb0815","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"10","author":"Schuetz","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1186\/s13613-023-01134-9_bb0820","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1473-3099(16)00065-7","article-title":"Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis","volume":"16","author":"Schuts","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0825","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/cid\/ciy550","article-title":"Antimicrobial stewardship and intensive care unit mortality: a systematic review","volume":"68","author":"Lindsay","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0830","article-title":"Interventions to improve antibiotic prescribing practices for hospital inpatients","volume":"2","author":"Davey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1186\/s13613-023-01134-9_bb0835","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1473-3099(17)30325-0","article-title":"Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis","volume":"17","author":"Baur","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0840","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1186\/s12879-022-07906-1","article-title":"Impact of antimicrobial stewardship on antibiogram, consumption and incidence of multi drug resistance","volume":"22","author":"Darwish","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0845","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/jac\/dkz113","article-title":"Implementation of antibiotic stewardship programmes in French ICUs in 2018: a nationwide cross-sectional survey","volume":"74","author":"Delannoy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0850","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00134-017-4682-7","article-title":"The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship","volume":"43","author":"Kollef","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0855","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/ciw217","article-title":"Executive summary: implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0860","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1128\/AAC.01535-08","article-title":"Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa","volume":"53","author":"Pakyz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01134-9_bb0865","doi-asserted-by":"crossref","first-page":"070","DOI":"10.1093\/ofid\/ofab070","article-title":"The effect of antibiotic restriction programs on prevalence of antimicrobial resistance: a systematic review and meta-analysis","volume":"8","author":"Schuts","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0870","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"10.1186\/s13613-023-01134-9_bb0875","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0880","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0885","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ajic.2011.07.011","article-title":"Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes","volume":"40","author":"DiazGranados","year":"2012","journal-title":"Am J Infect Control"},{"key":"10.1186\/s13613-023-01134-9_bb0890","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1086\/664757","article-title":"Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis","volume":"33","author":"Elligsen","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1186\/s13613-023-01134-9_bb0895","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1111\/1469-0691.12062","article-title":"Clinical impact of unsolicited post-prescription antibiotic review in surgical and medical wards: a randomized controlled trial","volume":"19","author":"Lesprit","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01134-9_bb0900","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/cid\/ciab747","article-title":"Impact of antibiotic stewardship rounds in the intensive care setting: a prospective cluster-randomized crossover study","volume":"74","author":"Seidelman","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0905","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ajic.2015.04.200","article-title":"Impact of a clinical microbiology-intensive care consulting program in a cardiothoracic intensive care unit","volume":"43","author":"Arena","year":"2015","journal-title":"Am J Infect Control"},{"key":"10.1186\/s13613-023-01134-9_bb0910","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CCM.0000000000003514","article-title":"Long-term effects of phased implementation of antimicrobial stewardship in academic ICUs: 2007\u20132015","volume":"47","author":"Morris","year":"2019","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0915","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13613-021-00917-2","article-title":"Antimicrobial stewardship, therapeutic drug monitoring and infection management in the ICU: results from the international A\u2014TEAMICU survey","volume":"11","author":"Lanckohr","year":"2021","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-023-01134-9_bb0920","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00134-020-06338-2","article-title":"Respiratory microbiome in mechanically ventilated patients: a narrative review","volume":"47","author":"Fromentin","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0925","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/cid\/ciz1052","article-title":"Assessing the ecological benefit of antibiotic de-escalation strategies to elaborate evidence-based recommendations","volume":"71","author":"Woerther","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb0930","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1007\/s00134-016-4339-y","article-title":"Alternatives to antibiotics","volume":"42","author":"Fran\u00e7ois","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0935","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/antibiotics9120916","article-title":"Developing diagnostic and therapeutic approaches to bacterial infections for a new era: implications of globalization","volume":"9","author":"Fern\u00e1ndez","year":"2020","journal-title":"Antibiotics"},{"key":"10.1186\/s13613-023-01134-9_bb0940","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/thx.2007.090613","article-title":"Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies","volume":"63","author":"El Moussaoui","year":"2008","journal-title":"Thorax"},{"key":"10.1186\/s13613-023-01134-9_bb0945","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1164\/ajrccm.162.2.9909095","article-title":"Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription","volume":"162","author":"Singh","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0950","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"el Moussaoui","year":"2006","journal-title":"BMJ"},{"key":"10.1186\/s13613-023-01134-9_bb0955","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb0960","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","article-title":"Discontinuing \u03b2-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial","volume":"397","author":"Dinh","year":"2021","journal-title":"Lancet"},{"key":"10.1186\/s13613-023-01134-9_bb0965","doi-asserted-by":"crossref","unstructured":"Montravers P, Dupont H, Leone M, Constantin J-M, Mertes P-M, Soci\u00e9t\u00e9 fran\u00e7aise d\u2019anesth\u00e9sie et de r\u00e9animation (Sfar), et al. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34:117\u201130.","DOI":"10.1016\/j.accpm.2015.03.005"},{"key":"10.1186\/s13613-023-01134-9_bb0970","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00134-018-5088-x","article-title":"Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial","volume":"44","author":"Montravers","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb0975","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks\u2019 treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam","volume":"223","author":"Jernelius","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1186\/s13613-023-01134-9_bb0980","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0924-8579(95)00011-V","article-title":"A sequential study of intravenous and oral Fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections","volume":"6","author":"de Gier","year":"1995","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01134-9_bb0985","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"10.1186\/s13613-023-01134-9_bb0990","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"10.1186\/s13613-023-01134-9_bb0995","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"10.1186\/s13613-023-01134-9_bb1000","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","article-title":"Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis","volume":"164","author":"Hepburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1186\/s13613-023-01134-9_bb1005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1186\/s13613-023-01134-9_bb1010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb1015","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1186\/s13613-023-01134-9_bb1020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"key":"10.1186\/s13613-023-01134-9_bb1025","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-023-01134-9_bb1030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13613-020-00713-4","article-title":"Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit","volume":"10","author":"Timsit","year":"2020","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-023-01134-9_bb1035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.rmr.2017.03.034","article-title":"Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise (summary)","volume":"34","author":"Jouneau","year":"2017","journal-title":"Revue des Maladies Respir"},{"key":"10.1186\/s13613-023-01134-9_bb1040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"Med Mal Infect"},{"key":"10.1186\/s13613-023-01134-9_bb1045","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01134-9_bb1050","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-023-01134-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025005916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025005916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:38:01Z","timestamp":1776670681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025005916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":209,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2110582025005916"],"URL":"https:\/\/doi.org\/10.1186\/s13613-023-01134-9","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic stewardship in the ICU: time to shift into overdrive","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-023-01134-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The Author(s) 2023. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"39"}}